Hiroaki Ueno, Masamitsu Nakazato. Show Affiliations »
Abstract
Mesh： See more » Anti-Obesity Agents/administration & dosageAnti-Obesity Agents/adverse effectsAnti-Obesity Agents/pharmacologyAppetite/drug effectsAppetite DepressantsBenzazepinesBenzoxazinesBupropionClinical Trials as TopicDrug ApprovalDrug CombinationsDrug Discovery/trendsEnergy Metabolism/drug effectsEnzyme InhibitorsFructose/analogs & derivativesGlucagon-Like Peptide 1/agonistsGlucagon-Like Peptide 1/analogs & derivativesHumansHypothalamus/physiologyLactonesLipase/antagonists & inhibitorsLiraglutideMetabolic Syndrome/etiologyNaltrexoneObesity/complicationsObesity/drug therapyOrlistatPhentermineTopiramate
Substances： See more » Anti-Obesity AgentsAppetite DepressantsBenzazepinesBenzoxazinesDrug CombinationsEnzyme InhibitorsLactonesQsymiabupropion hydrochloride, naltrexone hydrochoride drug combinationBupropionTopiramateFructoseNaltrexonelorcaserinLiraglutideGlucagon-Like Peptide 1OrlistatPhentermineLipasecetilistat
Year: 2014 PMID： 24796150 DOI： 10.2169/naika.103.753
Source DB: PubMed Journal: Nihon Naika Gakkai Zasshi ISSN： 0021-5384